**Research Study Seeks Multiple Sclerosis Patients Taking Ocrelizumab Who Have Not Yet Received COVID-19 Vaccine**

Investigator: Dr. Amanda Piquet, MD

COMIRB #: 21-3126

Researchers from the University of Colorado are conducting a study to investigate the immune response to the COVID vaccine in multiple sclerosis patients treated with Ocrevus.

Participants in this research study will provide 5 blood samples over the course of 1 year at timepoints both before and after their vaccination.

**You may be eligible to participate if you:**

* are between 18-65 years old
* are currently prescribed Ocrevus for your MS
* have not yet received an mRNA COVID vaccine (but are planning to)

Study participation will last for approximately 1 year. Compensation provided.

If you are interested in participating, please contact **Tyler Borko** by calling **(303) 724-0864** or by email at **Tyler.Borko@cuanschutz.edu****.**